JP2005532038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532038A5 JP2005532038A5 JP2003566021A JP2003566021A JP2005532038A5 JP 2005532038 A5 JP2005532038 A5 JP 2005532038A5 JP 2003566021 A JP2003566021 A JP 2003566021A JP 2003566021 A JP2003566021 A JP 2003566021A JP 2005532038 A5 JP2005532038 A5 JP 2005532038A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- molecule
- sirna
- rna
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 21
- 230000000295 complement effect Effects 0.000 claims 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 102000002262 Thromboplastin Human genes 0.000 claims 5
- 108010000499 Thromboplastin Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 239000007928 intraperitoneal injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20020612A NO20020612D0 (no) | 2002-02-07 | 2002-02-07 | Posttranskripsjonell inhibering ved korte interfererende RNA |
| US35451502P | 2002-02-08 | 2002-02-08 | |
| NO20024987A NO20024987D0 (no) | 2002-02-07 | 2002-10-16 | Posttranskripsjonell inhibering ved korte interfererende RNA'er |
| PCT/NO2003/000045 WO2003066650A2 (en) | 2002-02-07 | 2003-02-06 | Short interfering rna molecules directed towards a tissue factor coding nucleic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532038A JP2005532038A (ja) | 2005-10-27 |
| JP2005532038A5 true JP2005532038A5 (OSRAM) | 2006-01-05 |
| JP4335012B2 JP4335012B2 (ja) | 2009-09-30 |
Family
ID=27738950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003566021A Expired - Fee Related JP4335012B2 (ja) | 2002-02-07 | 2003-02-06 | 短い干渉ＲＮＡ（ｓｈｏｒｔｉｎｔｅｒｆｅｒｉｎｇＲＮＡ）による転写後抑制 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1554381B1 (OSRAM) |
| JP (1) | JP4335012B2 (OSRAM) |
| AT (1) | ATE449846T1 (OSRAM) |
| AU (1) | AU2003206267B2 (OSRAM) |
| CA (1) | CA2475447A1 (OSRAM) |
| DE (1) | DE60330263D1 (OSRAM) |
| DK (1) | DK1554381T3 (OSRAM) |
| ES (1) | ES2336440T3 (OSRAM) |
| WO (1) | WO2003066650A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534996A1 (en) * | 2003-08-06 | 2005-05-06 | Hans Prydz | The use of sirna silencing in the prevention of metastasis |
| US7919583B2 (en) | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
| WO2010008562A2 (en) | 2008-07-16 | 2010-01-21 | Recombinetics | Methods and materials for producing transgenic animals |
| WO2011084193A1 (en) * | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387366B1 (en) * | 1998-12-31 | 2002-05-14 | Alg Company | Methods for reducing adverse side effects associated with cellular transplantation |
| US7045350B2 (en) * | 2001-08-30 | 2006-05-16 | Mount Sinai School Of Medicine Of New York University | Alternatively spliced circulating tissue factor |
-
2003
- 2003-02-06 DK DK03703543.3T patent/DK1554381T3/da active
- 2003-02-06 WO PCT/NO2003/000045 patent/WO2003066650A2/en not_active Ceased
- 2003-02-06 JP JP2003566021A patent/JP4335012B2/ja not_active Expired - Fee Related
- 2003-02-06 DE DE60330263T patent/DE60330263D1/de not_active Expired - Lifetime
- 2003-02-06 EP EP03703543A patent/EP1554381B1/en not_active Expired - Lifetime
- 2003-02-06 AU AU2003206267A patent/AU2003206267B2/en not_active Ceased
- 2003-02-06 AT AT03703543T patent/ATE449846T1/de not_active IP Right Cessation
- 2003-02-06 ES ES03703543T patent/ES2336440T3/es not_active Expired - Lifetime
- 2003-02-06 CA CA002475447A patent/CA2475447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010306639B2 (en) | HBV antisense inhibitors | |
| JP4709545B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| RU2007101039A (ru) | Иммуностимулирующие олигонуклеотидные мультимеры | |
| JP2005506087A5 (OSRAM) | ||
| CN111557939A (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| CA2520541A1 (en) | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | |
| MX2015002491A (es) | Metodos para el tratamiento de infecciones de hepatitis b y hepatitis d. | |
| JP2010532163A5 (OSRAM) | ||
| EA036745B1 (ru) | Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d | |
| TW201923080A (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| WO2009143292A2 (en) | Method of treating pneumoconiosis with oligodeoxynucleotides | |
| EP2207555B1 (en) | Oligonucleotides for the treatment or alleviation of edema | |
| US7678774B2 (en) | Treating severe acute respiratory syndrome | |
| CN102973554B (zh) | 土木香内酯在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| CN112534055A (zh) | 用于调节rtel1表达的寡核苷酸 | |
| JP2005532038A5 (OSRAM) | ||
| JP2007530431A5 (OSRAM) | ||
| CN102337263B (zh) | 抑制肠道病毒71型基因表达的siRNA及组合物和应用 | |
| CN118086310B (zh) | 一种用于抑制circATF7IP基因表达的siRNA、递送系统及应用 | |
| WO2007084359A2 (en) | Compositions and methods for the treatment of influenza infection | |
| EP0807172A1 (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
| CN118202046A (zh) | 具有降低的脱靶效应的经修饰的小干扰rna分子 | |
| CN116687932B (zh) | ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯的医药用途 | |
| EP4652273A1 (en) | Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection |